Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for REM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | REM1 Recombinant Protein (Full-Length / Truncated) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View REM1 Products |
| Gene Delivery | REM1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View REM1 Products |
| Benchmark Ab | Anti-REM1 Recombinant Antibody Recombinant positive control for assay validation. |
View REM1 Products |
| Validator | REM1 siRNA Set For knockdown verification. |
View REM1 Products |
| Related Target A | CACNB2 L-type calcium channel beta-2 subunit; primary binding partner of REM1 for channel inhibition. |
View CACNB2 Products |
| Related Target B | CACNA1C CaV1.2 alpha-1C subunit; downstream effector regulated by the REM1-CaVbeta complex. |
View CACNA1C Products |
| Related Target C | RHOA Rho GTPase; synergistic pathway partner involved in cytoskeletal remodeling and migration. |
View RHOA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Targeting Intracellular PPI (REM1-CaVβ) | High-purity, sequence-verified REM1 and CACNB2 recombinant proteins available for robust in vitro binding assays. |
| Cell-Based Conformation & Functional Screening | Lentiviral vectors optimized for stable cell line construction to perform real-time calcium flux and electrophysiology assays. |
| Lack of Controls | Sequence-verified Benchmark Antibodies and validated positive controls included in the catalog. |
| False Positives in Knockdown | Chemically synthesized siRNA pools specifically designed for target gene validation. |
Live REM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for REM1 therapeutics is intensifying, with major players shifting focus from traditional small molecules to targeted protein-protein interaction (PPI) modulators and gene therapies. As first-generation calcium channel regulators reach clinical validation, the next wave of R&D is targeting the intracellular RGK family to treat cardiac arrhythmias, heart failure, and metastatic solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | Cardiac Arrhythmia, Hypertrophy | In vitro binding assays (Requires high-purity REM1 and CACNB2 proteins) |
| Gene Therapy (AAV/Lentivirus) | Cardiovascular Gene Therapy Developers | Heart Failure, Channelopathies | Stable cell line construction (Requires Lentiviral Premade Particles) |
| siRNA / RNAi Therapeutics | RNAi Specialists | Oncology (Metastasis, Angiogenesis) | Target validation & knockdown screening (Requires validated siRNA sets) |